Moderator: SABCS Co-director Virginia Kaklamani, MD, leader of the Breast Cancer Program at UT Health San Antonio
Abstracts are appended to the bottom of each news release (WEBCASTS at the bottom):
ABSTRACT Publication Number: GS5-00 Long-term influence of estrogen plus progestin and estrogen alone use on breast cancer incidence: The Women's health initiative randomized trials
Rowan T Chlebowski, Garnet L Anderson, Aaron K Aragaki, JoAnn E Manson, et al. SLIDES
Conclusions: CEE-alone and CEE plus MPA use have opposite effects on breast cancer incidence. CEE alone significantly decreases breast cancer incidence which is long term and persists over a decade after discontinuing use. CEE plus MPAuse significantly increases breast cancer incidence which is long term and persists over a decade after discontinuing use. As a result of the attenuation of subgroup interactions: all postmenopausal women with prior hysterectomy using CEE-alone have the potential benefit of experiencing a reduction in breast cancer incidence while all postmenopausal women using CEE plus MPA have the potential risk of experiencing an increase in breast cancer incidence.
ABSTRACT Publication Number: GS5-01 Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer: A multi-center pooled analysis
Christina Yau, Marieke van der Noordaa, Jane Wei, Marie Osdoit, et al. SLIDES
Conclusions: While not all cancer centers routinely collect data on residual cancer burden, this analysis shows that pathologists can implement it with accurate results, adding to its potential as a predictor of recurrence within breast cancer subtypes.
ABSTRACT Publication Number: GS5-02 Detection of circulating tumor DNA (ctDNA) after neoadjuvant chemotherapy is significantly associated with disease recurrence in early-stage triple-negative breast cancer (TNBC): Preplanned correlative results from clinical trial BRE12-158
Milan Radovich, Guanglong Jiang, Christopher Chitambar, Rita Nanda, et al. SLIDES
Conclusions: Detection of ctDNA in early-stage TNBC after neoadjuvant chemotherapy is an independent predictor of disease recurrence, and represents an important novel stratification factor for future post-neoadjuvant trials.
ABSTRACT Publication Number: GS6-01 Oral paclitaxel with encequidar: The first orally administered paclitaxel shown to be superior to IV paclitaxel on confirmed response and survival with less neuropathy: A phase III clinical study in metastatic breast cancer
David L Cutler, Gerardo Umanzor, Francisco J Barrios, Rosa H Vassallo, et al. SLIDES
Conclusion: Oral paclitaxel + encequidar is the first orally administered paclitaxel shown to be superior to IV paclitaxel for confirmed response, progression-free survival, and overall survival, with minimal clinically meaningful neuropathy.